RESOURCES

Olivier Mirguet, PhD
Global Head of Chemistry Strategy & Innovation –Eurofins Discovery

Antibody-drug conjugates (ADCs) represent a novel class of therapeutic agents that allow the targeted delivery of cytotoxic payloads to tumor cells via the selectivity afforded by monoclonal antibodies (mAbs) directed against tumors expressing particular antigens. When the mAb component of the ADC binds to its cell surface antigen, the ADC-antigen complex is internalized by the cancer cell.

Checkpoint blockade antibodies, or checkpoint inhibitors, are established as effective cancer therapeutics.

WRN is found to be upregulated in many human cancers. Indeed, this helicase has various roles in replication, base excision repair, recombination, DNA damage response and transcription.

The androgen receptor (AR) plays a central role in the progression of prostate cancer, where AR signaling can drive tumor cell growth and survival.

Eurofins DiscoverX’s KILR^®️ cytotoxicity assay platform accurately measures the killing of antigen-expressing target cells in co-culture with immune effector cells.

Lung cancer is the leading cause of cancer-related deaths worldwide, with non-small cell lung carcinoma (NSCLC) accounting for 85% of cases and associated with poor prognosis.

Accelerate Your Drug Discovery with Our State-of-the-Art Chemistry Services

A novel affinity-based screening approach using the Spectral Shift (SpS) technology was developed at Eurofins Discovery for hit finding programs.

Understanding a drug’s mechanism of action and potential side effects is vital for drug discovery. This study demonstrates the utility of KINOMEscan^®️, a high-throughput screening platform, to evaluate fifteen FDA-approved or clinical-stage BTK inhibitors.

Prediction of ADMET properties and off-target liabilities improves small molecule drug discovery efficiency. The EMERALD database, containing over 90,000 unique compounds and millions of experimental data points, provides a solid foundation for AI/ML tool development.

Two hot and emerging areas in drug discovery include the E3 ligases in targeted protein degradation (TPD) and SRC homology 2 (SH2) domain-containing proteins.